Department of Medical Laboratory Science, Faculty of Allied Health Sciences, University of Ruhuna, Galle, Sri Lanka.
Department of Biochemistry, Faculty of Medicine, University of Ruhuna, Galle, Sri Lanka.
J Ethnopharmacol. 2022 Jun 28;292:115221. doi: 10.1016/j.jep.2022.115221. Epub 2022 Mar 23.
Ambrette (Abelmoschus moschatus Medik., Family: Malvaceae) is a common Ayurvedic herbal medicine used in the treatment of kidney-related diseases, in the forms of tea, medicated oil, medicated wine, etc., however, its nephroprotective mechanisms remain unexploited.
To investigate the mechanisms by which the hexane (A-HE), ethyl acetate (A-EE), butanol (A-BE), and aqueous (A-WE) leaf extracts of Ambrette protect against the adriamycin-mediated acute kidney injury in Wistar rats.
A-HE, A-EE, A-BE, A-WE, and fosinopril sodium were administered at therapeutically effective doses (55, 75, 60, 140, 0.09 mg/kg) to adriamycin-induced (5 mg/kg, ip) Wistar rats for 28 consecutive days.
Oral administration of the selected extracts of A. moschatus resulted in amelioration of kidney injury as observed by the significant changes of biomarkers of kidney function in serum and in urine, biochemical parameters of oxidative stress, and inflammation in kidney homogenates (p < 0.05). Furthermore, the administration of plant extracts caused a significant reduction in total kidney injury scores in H and E stained kidney sections (p < 0.05). The immunohistochemical expression of the inflammatory marker, COX-2, and the pro-apoptotic marker, Bax, were attenuated and the expression of the anti-apoptotic marker, BCL-2, was increased. A-HE exerted superior nephroprotective effects over the other three extracts and the drug reference standard.
The findings revealed that Ambrette exerts promising protective effects against adriamycin-mediated acute kidney injury through antioxidant, anti-inflammatory, and anti-apoptosis pathways. A-HE might serve as a potential candidate for the development of therapeutic drug leads that will be beneficial in the treatment of acute kidney injury.
藏红花（Abelmoschus moschatus Medik.，锦葵科）是一种常见的阿育吠陀草药，用于治疗肾脏相关疾病，形式有茶、药用油、药用酒等，但它的肾脏保护机制尚未被开发。
研究藏红花叶的己烷（A-HE）、乙酸乙酯（A-EE）、正丁醇（A-BE）和水（A-WE）提取物通过何种机制防止阿霉素引起的 Wistar 大鼠急性肾损伤。
阿霉素（5mg/kg，ip）诱导的 Wistar 大鼠连续 28 天给予 A-HE、A-EE、A-BE、A-WE 和福辛普利钠治疗有效剂量（55、75、60、140、0.09mg/kg）。
口服藏红花提取物可改善肾功能，血清和尿液中肾功能生物标志物、肾匀浆中氧化应激和炎症的生化参数均有显著变化（p<0.05）。此外，植物提取物的给药导致 H 和 E 染色肾切片中的总肾损伤评分显著降低（p<0.05）。炎症标志物 COX-2 和促凋亡标志物 Bax 的免疫组化表达减弱，抗凋亡标志物 BCL-2 的表达增加。A-HE 对其他三种提取物和药物参考标准的肾脏保护作用优于其他三种提取物。
这些发现表明，藏红花通过抗氧化、抗炎和抗细胞凋亡途径对阿霉素诱导的急性肾损伤发挥了有希望的保护作用。A-HE 可能成为开发治疗药物先导物的潜在候选药物，这将有利于治疗急性肾损伤。
